XTL Biopharmaceuticals (NASDAQ:XTLB) Shares Pass Above 50-Day Moving Average – Here’s Why

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.57 and traded as high as $2.74. XTL Biopharmaceuticals shares last traded at $2.70, with a volume of 45,674 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, XTL Biopharmaceuticals presently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

The firm has a market capitalization of $5.94 million, a price-to-earnings ratio of -4.22 and a beta of 1.45. The company has a fifty day moving average price of $2.57 and a 200-day moving average price of $3.35.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.